{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:41Z","timestamp":1792828781649,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT is an imaging modality of high performance in multiple myeloma (MM). Nevertheless, the inter-observer reproducibility in PET\/CT scan interpretation may be hampered by the different patterns of bone marrow (BM) infiltration in the disease. Although many approaches have been recently developed to address the issue of standardization, none can yet be considered a standard method in the interpretation of PET\/CT. We herein aim to validate a novel three-dimensional deep learning-based tool on PET\/CT images for automated assessment of the intensity of BM metabolism in MM patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Whole-body [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT scans of 35 consecutive, previously untreated MM patients were studied. All patients were investigated in the context of an open-label, multicenter, randomized, active-controlled, phase 3 trial (GMMG-HD7). Qualitative (visual) analysis classified the PET\/CT scans into three groups based on the presence and number of focal [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-avid lesions as well as the degree of diffuse [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake in the BM. The proposed automated method for BM metabolism assessment is based on an initial CT-based segmentation of the skeleton, its transfer to the SUV PET images, the subsequent application of different SUV thresholds, and refinement of the resulting regions using postprocessing. In the present analysis, six different SUV thresholds (Approaches 1\u20136) were applied for the definition of pathological tracer uptake in the skeleton [Approach 1: liver SUV\n                      <jats:sub>median<\/jats:sub>\n                      \u2009\u00d7\u20091.1 (axial skeleton), gluteal muscles SUV\n                      <jats:sub>median<\/jats:sub>\n                      \u2009\u00d7\u20094 (extremities). Approach 2: liver SUV\n                      <jats:sub>median<\/jats:sub>\n                      \u2009\u00d7\u20091.5 (axial skeleton), gluteal muscles SUV\n                      <jats:sub>median<\/jats:sub>\n                      \u2009\u00d7\u20094 (extremities). Approach 3: liver SUV\n                      <jats:sub>median<\/jats:sub>\n                      \u2009\u00d7\u20092 (axial skeleton), gluteal muscles SUV\n                      <jats:sub>median<\/jats:sub>\n                      \u2009\u00d7\u20094 (extremities). Approach 4:\u2009\u2265\u20092.5. Approach 5:\u2009\u2265\u20092.5 (axial skeleton),\u2009\u2265\u20092.0 (extremities). Approach 6: SUV\n                      <jats:sub>max<\/jats:sub>\n                      liver]. Using the resulting masks, subsequent calculations of the whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in each patient were performed. A correlation analysis was performed between the automated PET values and the results of the visual PET\/CT analysis as well as the histopathological, cytogenetical, and clinical data of the patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BM segmentation and calculation of MTV and TLG after the application of the deep learning tool were feasible in all patients. A significant positive correlation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) was observed between the results of the visual analysis of the PET\/CT scans for the three patient groups and the MTV and TLG values after the employment of all six [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake thresholds. In addition, there were significant differences between the three patient groups with regard to their MTV and TLG values for all applied thresholds of pathological tracer uptake. Furthermore, we could demonstrate a significant, moderate, positive correlation of BM plasma cell infiltration and plasma levels of \u03b22-microglobulin with the automated quantitative PET\/CT parameters MTV and TLG after utilization of Approaches 1, 2, 4, and 5.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The automated, volumetric, whole-body PET\/CT assessment of the BM metabolic activity in MM is feasible with the herein applied method and correlates with clinically relevant parameters in the disease. This methodology offers a potentially reliable tool in the direction of optimization and standardization of PET\/CT interpretation in MM. Based on the present promising findings, the deep learning-based approach will be further evaluated in future prospective studies with larger patient cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06339-5","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T06:01:33Z","timestamp":1690351293000},"page":"3697-3708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Application of an artificial intelligence-based tool in [18F]FDG PET\/CT for the assessment of bone marrow involvement in multiple myeloma"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Enqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ul\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hajiyianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Edenbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"6339_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/bjh.12007","volume":"159","author":"E Zamagni","year":"2012","unstructured":"Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(5):499\u2013513.https:\/\/doi.org\/10.1111\/bjh.12007.","journal-title":"Br J Haematol"},{"key":"6339_CR2","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1200\/EDBK_159074","volume":"35","author":"E Terpos","year":"2016","unstructured":"Terpos E, Dimopoulos MA, Moulopoulos LA. The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book. 2016;35:e407\u201317. https:\/\/doi.org\/10.1200\/EDBK_159074.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"6339_CR3","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206\u201317.","journal-title":"Lancet Oncol"},{"issue":"7","key":"6339_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: how? When? Blood. 2019;133(7):644\u201351.","journal-title":"Blood"},{"issue":"6","key":"6339_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.semnuclmed.2015.02.006","volume":"45","author":"AJ Corrigan","year":"2015","unstructured":"Corrigan AJ, Schleyer PJ, Cook GJ. Pitfalls and artifacts in the use of PET\/CT in oncology imaging. Semin Nucl Med. 2015;45(6):481\u201399.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"6339_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130(1):30\u20134.","journal-title":"Blood"},{"issue":"3","key":"6339_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43(3):414\u201321.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"6339_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712\u20139.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6339_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","volume":"53","author":"R Fonti","year":"2012","unstructured":"Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829\u201335.","journal-title":"J Nucl Med"},{"issue":"23","key":"6339_CR10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","volume":"15","author":"JE McDonald","year":"2017","unstructured":"McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;15(23):1981\u20137.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"6339_CR11","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.3324\/haematol.2018.213041","volume":"104","author":"C Sachpekidis","year":"2019","unstructured":"Sachpekidis C, Merz M, Kopp-Schneider A, Jauch A, Raab MS, Sauer S, et al. Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography\/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. Haematologica. 2019;104(9):e420\u20133.","journal-title":"Haematologica"},{"issue":"2","key":"6339_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjh.16633","volume":"191","author":"T Terao","year":"2020","unstructured":"Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, et al. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography\/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020;191(2):223\u201330.","journal-title":"Br J Haematol"},{"issue":"2","key":"6339_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jacr.2017.09.044","volume":"15","author":"P Lakhani","year":"2018","unstructured":"Lakhani P, Prater AB, Hutson RK, Andriole KP, Dreyer KJ, Morey J, et al. Machine learning in radiology: applications beyond image interpretation. J Am Coll Radiol. 2018;15(2):350\u20139.","journal-title":"J Am Coll Radiol"},{"issue":"1","key":"6339_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40658-020-00316-9","volume":"7","author":"E Tr\u00e4g\u00e5rdh","year":"2020","unstructured":"Tr\u00e4g\u00e5rdh E, Borrelli P, Kaboteh R, Gillberg T, Ul\u00e9n J, Enqvist O, Edenbrandt L. RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. EJNMMI Phys. 2020;7(1):51.","journal-title":"EJNMMI Phys"},{"issue":"2","key":"6339_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/neuonc\/noaa232","volume":"23","author":"SJ Cho","year":"2021","unstructured":"Cho SJ, Sunwoo L, Baik SH, Bae YJ, Choi BS, Kim JH. Brain metastasis detection using machine learning: a systematic review and meta-analysis. Neuro Oncol. 2021;23(2):214\u201325.","journal-title":"Neuro Oncol"},{"issue":"1","key":"6339_CR16","doi-asserted-by":"publisher","first-page":"15814","DOI":"10.1038\/s41598-021-95249-3","volume":"11","author":"S Soffer","year":"2021","unstructured":"Soffer S, Klang E, Shimon O, Barash Y, Cahan N, Greenspana H, Konen E. Deep learning for pulmonary embolism detection on computed tomography pulmonary angiogram: a systematic review and meta-analysis. Sci Rep. 2021;11(1):15814.","journal-title":"Sci Rep"},{"key":"6339_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.110073","volume":"146","author":"M Daugaard J\u00f8rgensen","year":"2022","unstructured":"Daugaard J\u00f8rgensen M, Antulov R, Hess S, Lysdahlgaard S. Convolutional neural network performance compared to radiologists in detecting intracranial hemorrhage from brain computed tomography: a systematic review and meta-analysis. Eur J Radiol. 2022;146: 110073.","journal-title":"Eur J Radiol"},{"issue":"11","key":"6339_CR18","doi-asserted-by":"publisher","first-page":"7998","DOI":"10.1007\/s00330-022-08784-6","volume":"32","author":"BS Kelly","year":"2022","unstructured":"Kelly BS, Judge C, Bollard SM, Clifford SM, Healy GM, Aziz A, et al. Radiology artificial intelligence: a systematic review and evaluation of methods (RAISE). Eur Radiol. 2022;32(11):7998\u20138007 (Erratum in: Eur Radiol. 2022 May 20).","journal-title":"Eur Radiol."},{"key":"6339_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2022.110247","volume":"150","author":"X Liang","year":"2022","unstructured":"Liang X, Yu X, Gao T. Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Eur J Radiol. 2022;150: 110247.","journal-title":"Eur J Radiol"},{"issue":"12","key":"6339_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"11","key":"6339_CR21","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810\u201321.","journal-title":"Lancet Haematol."},{"issue":"2","key":"6339_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bell\u00f2 M, et al. 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417\u201322.","journal-title":"Leukemia"},{"key":"6339_CR23","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma reated with total therapy 3. Blood. 2013;121:1819\u201323.","journal-title":"Blood"},{"key":"6339_CR24","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, Shaughnessy JDJr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376.","journal-title":"Blood"},{"issue":"1","key":"6339_CR25","doi-asserted-by":"publisher","first-page":"16429","DOI":"10.1038\/s41598-019-52740-2","volume":"9","author":"MES Takahashi","year":"2019","unstructured":"Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, et al. Proposal for a quantitative [18F]FDG PET\/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma. Sci Rep. 2019;9(1):16429.","journal-title":"Sci Rep"},{"issue":"21","key":"6339_CR26","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1158\/1078-0432.CCR-18-0741","volume":"24","author":"C Bailly","year":"2018","unstructured":"Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, et al. Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of \u0394SUVmax in the FDG-Avid Patients of the IMAJEM Study. Clin Cancer Res. 2018;24(21):5219\u201324.","journal-title":"Clin Cancer Res"},{"key":"6339_CR27","first-page":"433","volume-title":"MeyerF","author":"S Beucher","year":"2018","unstructured":"Beucher S. MeyerF. The Morphological Approach to Segmentation: The Watershed Transformation. Mathematical Morphology in Image Processing. CRC Press; 2018. p. 433\u201381."},{"issue":"26","key":"6339_CR28","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"6339_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/MNM.0000000000001470","volume":"42","author":"MES Takahashi","year":"2021","unstructured":"Takahashi MES, Mosci C, Duarte GO, Pericole FV, Metze K, Lorand-Metze IGH, Ramos CD. Intensity of bone involvement: a quantitative 18F-FDG PET\/CT evaluation for monitoring outcome of multiple myeloma. Nucl Med Commun. 2021;42(12):1375\u201381.","journal-title":"Nucl Med Commun"},{"issue":"23","key":"6339_CR30","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989\u201395 (Erratum in: Blood. 2012 Sep 13;120(11):234).","journal-title":"Blood."},{"key":"6339_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","volume":"75","author":"BG Durie","year":"1990","unstructured":"Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group sStudy. Blood. 1990;75:823\u201330.","journal-title":"Blood"},{"key":"6339_CR32","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","volume":"97","author":"T Facon","year":"2001","unstructured":"Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevi\u00e8ve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566\u201371.","journal-title":"Blood"},{"key":"6339_CR33","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6339_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","volume":"20","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, et al. Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2020;20(9):596\u2013601.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"6339_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/147323000703500207","volume":"35","author":"S Zincirkeser","year":"2007","unstructured":"Zincirkeser S, \u015eahin E, Halac M, Sager S. Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging. J Int Med Res. 2007;35(2):231\u20136.","journal-title":"J Int Med Res."},{"issue":"10","key":"6339_CR36","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.2967\/jnumed.115.159715","volume":"56","author":"O Gheysens","year":"2015","unstructured":"Gheysens O, Postnov A, Deroose CM, Vandermeulen C, de Hoon J, Declercq R, et al. Quantification, variability, and reproducibility of basal skeletal muscle glucose uptake in healthy humans using 18F-FDG PET\/CT. J Nucl Med. 2015;56(10):1520\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"6339_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-022-00884-0","volume":"12","author":"AH Dias","year":"2022","unstructured":"Dias AH, Hansen AK, Munk OL, Gormsen LC. Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients. EJNMMI Res. 2022;12(1):15.","journal-title":"EJNMMI Res"},{"issue":"5","key":"6339_CR38","first-page":"286","volume":"33","author":"M Aras","year":"2014","unstructured":"Aras M, Dede F, Ones T, Inan\u0131r S, Erd\u0131l TY, Turoglu HT. Evaluation of physiological FDG uptake in the skeleton in adults: is it uniformly distributed? Rev Esp Med Nucl Imagen Mol. 2014;33(5):286\u20139.","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"issue":"8","key":"6339_CR39","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1007\/s00330-021-07687-2","volume":"31","author":"T Terao","year":"2021","unstructured":"Terao T, Machida Y, Narita K, Kuzume A, Tabata R, Tsushima T, et al. Total diffusion volume in MRI vs. total lesion glycolysis in PET\/CT for tumor volume evaluation of multiple myeloma. Eur Radiol. 2021;31(8):6136\u201344.","journal-title":"Eur Radiol."},{"issue":"6","key":"6339_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s13244-010-0062-3","volume":"2","author":"NM Long","year":"2011","unstructured":"Long NM, Smith CS. Causes and imaging features of false positives and false negatives on F-PET\/CT in oncologic imaging. Insights Imaging. 2011;2(6):679\u201398.","journal-title":"Insights Imaging"},{"issue":"6","key":"6339_CR41","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302\u201312 (Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.).","journal-title":"Lancet Oncol."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06339-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:09:03Z","timestamp":1696309743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06339-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6339"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06339-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish has been received from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hartmut Goldschmidt declares the following:Grants and\/or provision of Investigational Medicinal Product:Amgen, Array Biopharma\/Pfizer, BMS\/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi.Research support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis.Advisory boards: Amgen, BMS, Janssen, Sanofi, Adaptive Biotechnology.Honoraria: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer.Support for attending meetings and\/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer.All other authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}